Related Experiment Video
Updated: Jun 19, 2026
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
Monica Milani1, Gautam Jha, David A Potter
1Department of Medicine, Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN, U.S.A.
Abstract:
The majority of breast cancers express the estrogen receptor and depend on estradiol (E2) for their growth. Hormonal therapy aims at depriving estrogen signaling either by using selective estrogen receptor modulators (SERM)-that interfere with the binding of E2 to its receptor (ER)-or aromatase inhibitors (AI)-that block the aromatase-dependent synthesis of E2. While SERMs are recommended for both pre- and post-menopausal patients, AIs are indicated only for post-menopausal patients. For the past 20 years, the SERM tamoxifen has been considered the "gold standard" for the treatment of hormone receptor positive breast cancers. However, tamoxifen's role is now challenged by third generation AIs, such as anastrozole, which exhibit greater efficacy in the adjuvant setting in several recently reported trials. This review will focus on anastrozole's mechanism of action, dosing, pharmacology, pharmacokinetics, and clinical applications. It will briefly discuss the clinical trials that determined anastrozole's efficacy in the treatment of advanced breast cancer (ABC) and in the neoadjuvant setting. Finally, it will present the clinical trials that established anastrozole as a frontline agent in the treatment of post-menopausal women with hormone receptor positive early breast cancer.
Insights
Anastrozole, a third-generation aromatase inhibitor (AI), shows greater efficacy than tamoxifen for hormone receptor-positive breast cancer. This review details anastrozole
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Estrogen receptor-positive breast cancers rely on estradiol (E2) for growth.
- Hormonal therapies include selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs).
- Aromatase inhibitors are indicated only for post-menopausal patients.
Purpose of the Study:
- To review anastrozole's mechanism of action, dosing, pharmacology, pharmacokinetics, and clinical applications.
- To discuss clinical trials evaluating anastrozole in advanced and neoadjuvant breast cancer.
- To present evidence establishing anastrozole as a frontline treatment for post-menopausal women with early breast cancer.
Main Methods:
- Review of clinical trials and pharmacological data.
- Focus on anastrozole's efficacy and safety profile.
- Comparison with traditional therapies like tamoxifen.
Main Results:
- Third-generation aromatase inhibitors, like anastrozole, demonstrate superior efficacy in the adjuvant setting.
- Anastrozole has established efficacy in advanced and neoadjuvant breast cancer treatment.
- Clinical trials support anastrozole as a frontline therapy for post-menopausal women with early hormone receptor-positive breast cancer.
Conclusions:
- Anastrozole represents a significant advancement in hormonal therapy for breast cancer.
- It offers a more effective alternative to tamoxifen for specific patient populations.
- Further research may continue to refine its role in breast cancer management.
Related Concept Videos
01:28Menopause
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...